The introduction of small-molecule tyrosine kinase inhibitors (TKIs) designed to target the FLT3 tyrosine kinase receptor has significantly improved both overall survival (OS) and event-free survival (EFS) rates in patients with FLT3-mutated AML [9]. Here, FLT3 is linked to acute myeloid leukemia.